Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: Supporting the benefits of combination therapy

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 969-978

  Clyburn, Rhys D ^a   Reid, Penny ^a   Evans, Catherine A ^a   Lefley, Diane V ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Chemotherapy; Combination therapy; Prostate cancer

Indexed keywords

DOXORUBICIN; GERANYLGERANIOL; MEVALONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL STRAIN LNCAP; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; STAINING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS;

EID: 77649178985     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1106-6     Document Type: Article

References (44)

1. L Ye HG Kynaston WG Jiang 2007 Bone metastasis in prostate cancer: molecular and cellular mechanisms Int J Mol Med 20 1 103 111 17549396
2. F Saad P Karakiewicz P Perrotte 2005 The role of bisphosphonates in hormone-refractory prostate cancer World J Urol 23 1 14 18 10.1007/s00345-004- 0472-2 15666171 (Pubitemid 40425166)
3. PD Ottewell H Mönkkönen M Jones DV Lefley RE Coleman I Holen 2008 Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer J Natl Cancer Inst 100 1167 1178 10.1093/jnci/djn240 18695136
4. PD Ottewell B Deux H Mönkkönen RE Coleman P Clezardin I Holen 2008 Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo Clin Cancer Res 14 4658 4666 10.1158/1078-0432.CCR-07-1545 18628481
5. MJ Rogers 2003 New insights into the molecular mechanisms of action of bisphosphonates Curr Pharm Des 9 32 2643 2658 10.2174/1381612033453640 14529538 (Pubitemid 37456015)
6. E Van Beek E Pieterman L Cohen C Lowik S Papapoulos 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-bisphosphonates Biochem Biophys Res Commun 264 108 111 10.1006/bbrc.1999.1499 10527849 (Pubitemid 29500472)
7. SP Luckman DE Hughes FP Coxon R Graham G Russell MJ Rogers 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 4 581 589 10.1359/jbmr.1998.13.4.581 9556058 (Pubitemid 28163009)
8. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P (2007) Bisphosphonates in cancer therapy. Cancer Lett 257(1):16-35
9. SG Senartne G Pirianov JL Mansi TR Arnett KW Colston 2000 Bisphosphonates induce apoptosis in human breast cancer cell lines Br J Cancer 82 8 1459 1468
10. JP Coxon GM Oades RS Kirby KW Colston 2004 Zoledronic acid induces apoptosis and inhibits adhesion to mineralised matrix in prostate cancer cells via inhibition of protein prenylation BJU Int 94 164 170 10.1111/j.1464-4096. 2004.04831.x 15217454 (Pubitemid 38980328)
11. CM Shipman MJ Rogers JF Apperley RG Russell PI Croucher 1997 Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity Br J Haematol 98 665 672 10.1046/j.1365-2141.1997.2713086.x 9332325
12. G van der Pluijm H Vloedgraven E van Beek L van der Wee-Pals C Lowik S Papapoulos 1996 Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro J Clin Invest 98 3 698 705 10.1172/JCI118841 8698861
13. S Boissier M Ferreras O Peyruchaud S Magnetto FH Ebetino M Colombel P Delmas JM Delaisse P Clezardin 2000 Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 2949 2954 10850442
14. SS Virtanen HK Vaananen PL Harkonen PT Lakkakorpi 2002 Alendronate inhibits invasion of PC3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 2708 2714 11980672
15. P Fournier S Boissier S Filleur J Guglielmi F Cabon M Colombel P Clezardin 2002 Bisphophonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 6238 6544
16. PI Croucher R De Hendrik MJ Perry A Hijzen CM Shipman J Lippitt J Green E van Marck B van Camp 2003 Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumour burden and angiogenesis, and increased survival J Bone Miner Res 18 3 482 492 10.1359/jbmr.2003.18.3.482 12619933 (Pubitemid 36241065)
17. E Giraudo M Inoue D Hanahan 2004 An amino-bisphosphonate targets MMP-9 expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 623 633 15343380
18. JR Green 2004 Bisphosphonates: preclinical review Oncologist 9 Suppl 4 3 13 10.1634/theoncologist.9-90004-3 15459425
19. D Santini M Caraglia B Vincenzi I Holen S Scarpa A Budillon G Tonini 2006 Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates Nat Clin Pract Oncol 3 6 325 338 10.1038/ncponc0520 16757970 (Pubitemid 43871543)
20. HL Neville-Webbe A Rostami-Hodjegan CA Evans RE Coleman I Holen 2005 Sequence and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells Int J Cancer 113 364 371 10.1002/ijc.20602 15455384 (Pubitemid 40038702)
21. A Ullen L Lennartsson U Harmenberg M Hjelm-Eriksson KM Kalkner B Lennernas 2005 Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid Acta Oncol 44 6 644 650 10.1080/02841860510029617 16165924 (Pubitemid 41503612)
22. P Tassone S Forciniti E Galea G Morrone MC Turco V Martinelli S Venuta 2000 Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines Leukaemia 14 841 844 10.1038/sj.leu.2401770 (Pubitemid 30235061)
23. KD Brubaker LG Brown RL Vessella E Corey 2006 Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment BMC Cancer 6 15 10.1186/1471-2407-6-15 16417633 (Pubitemid 43193496)
24. N Kroger W Achterrath S Hegewisch-Becker K Mross AR Zander 1999 Current options in treatment of anthracycline-resistant breast cancer Cancer Treat Rev 25 279 291 10.1053/ctrv.1999.0137 10544072 (Pubitemid 29507299)
25. FA Fornari Jr DW Jarvis S Grant MS Orr JK Randolph FK White DA Gewirtz 1996 Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin Biochem Pharmacol 51 7 931 940 10.1016/0006-2952(96)00050-0 8651943 (Pubitemid 26109490)
26. AJ Potter KA Gollahon BJ Palanca MJ Harbert YM Choi AH Moskovitz JD Potter PS Rabinovitch 2002 Flow cytometric analysis of the cell cycle phase specificity of DNA damage induced by radiation, hydrogen peroxide and doxorubicin Carcinogenesis 23 389 401 10.1093/carcin/23.3.389 11895853
27. KM Tewey TC Rowe L Yang BD Halligan LF Liu 1984 Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 466 468 10.1126/science.6093249 6093249
28. FA Fornari JK Randolph JC Yalowich MK Ritke DA Gewirtz 1994 Interference by doxorubicin with DNA unwinding in MCF-7 breast tumour cells Mol Pharmacol 45 649 656 8183243
29. FA Fornari Jr WD Jarvis S Grant MS Orr JK Randolph FK White VR Mumaw ET Lovings RH Freeman DA Gewirtz 1994 Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumour cells after continuous exposure to a sublethal concentration of doxorubicin Cell Growth Differ 5 723 733 7947387
30. GJ Goldenberg H Wang GW Blair 1986 Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single-and double-strand breakage in cloned cell lines of adriamycin-sensitive and-resistant P388 leukaemia Cancer Res 46 2978 2983 3698020
31. R Petrioli AI Fiaschi E Francini A Pascucci G Francini 2008 The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer Cancer Treat Rev 34 8 710 718 10.1016/j.ctrv.2008.05.004 18620815
32. S Mike C Harrison B Coles J Staffurth TJ Wilt MD Mason 2006 Chemotherapy for hormone-refractory prostate cancer Cochrane Database Syst Rev 18 4 CD005247
33. GM Oades SG Senaratne IA Clarke RS Kirby KW Colston 2003 Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing RAS membrane localization in prostate cancer cells The J Urol 170 246 252 10.1097/01.ju.0000070685.34760.5f (Pubitemid 36734471)
34. JE Brown RJ Cook P Major, et al. 2005 Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 59 69 15632381
35. NK Thudi CK Martin MV Nadella SA Fernandez JL Werbeck JJ Pinzone TJ Rosol 2008 Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions Prostate 68 10 1116 1125 10.1002/pros.20776 18461562 (Pubitemid 351875183)
36. E Corey LG Brown JE Quinn M Poot MP Roudier CS Higano RL Vessella 2003 Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer Clin Cancer Res 9 1 295 306 12538482
37. LW Chung A Baseman V Assikis HE Zhau 2005 Molecular insights into prostate cancer progression: the missing link of tumor microenvironment J Urol 173 1 10 20 15592017
38. GA Clines TA Guise 2008 Molecular mechanisms and treatment of bone metastasis Expert Rev Mol Med 6 10 e7 10.1017/S1462399408000616
39. K Sun-Jin U Hisanori Y Sertac H Junqin RL Robert M Paul F Dominic J Isaiah 2005 Fidler modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer Cancer Res 65 3707 3715 10.1158/0008-5472. CAN-04-3601 (Pubitemid 40616348)
40. van Beek ER, Lowik CW, van Wijngaarden J, Ebetino FH, Papapoulos SE (2008) Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast Cancer Res Treat [Epub ahead of print]
41. SP Jagdev RE Coleman CM Shipman HA Rostami PI Croucher 2001 The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with Paclitaxel Br J Cancer 84 8 1126 1134 10.1054/bjoc.2001.1727 11308265 (Pubitemid 32448513)
42. H Pandha L Birchall B Meyer N Wilson K Relph C Anderson K Harrington 2006 Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines J Urol 176 2255 2261 10.1016/j.juro.2006.07.053 17070308 (Pubitemid 44633143)
43. S Matsumoto S Kimura H Segawa J Kuroda T Yuasa K Sato M Nogawa F Tanaka T Maekawa H Wada 2005 Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines Lung Cancer 47 31 39 10.1016/j.lungcan.2004.06.003 15603852 (Pubitemid 39643239)
44. DR Budman A Calabro 2006 Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents Oncology 70 2 147 153 10.1159/000093006 16645328 (Pubitemid 43760341)